Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

Luke Maese, DO, Rachel E. Rau, MD, Elizabeth A. Raetz, MD, Tong Lin, Jin Zhu, Pil Kim, Reddy Chandula, Sherrie McClung, Julie Gray, Mi Rim Choi, MD, Mignon L. Loh, MD, Peter C. Adamson

Blood (2019) 134 (Supplement_1): 2586.

https://doi.org/10.1182/blood-2019-123710

Published: 2019

Journal Articles

Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2

Elizabeth A. Raetz, MD, Mitchell S. Cairo, MD, Michael J. Borowitz, MD, PhD, Xiaomin Lu, PhD, Meenakshi Devidas, PhD, Joel M. Reid, PhD, David M. Goldenberg, ScD, MD, William A Wegener, MD, PhD, James A. Whitlock, MD, Peter C. Adamson, MD, Stephen P Hunger, MD, William L. Carroll, MD

Blood (2011) 118 (21): 573.

https://doi.org/10.1182/blood.V118.21.573.573

Published: 2011

Journal Articles

Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group

Richard Aplenc, MD, PhD, Brian T. Fisher, DO, MSCE, Lillian Sung, MD, PhD, Ron Keren, MD, MSCE, Todd A. Alonzo, PhD, Mathew Hall, PhD, Yuan-Shung V. Huang, MS, Yimei Li, PhD, Xianqun Luan, PhD, Robert B. Gerbing, M.A., David Bertoch, MS, Alix E. Seif, MD, MPH, Peter C. Adamson, MD, Alan S. Gamis, MD, MPH

Blood (2011) 118 (21): 2617.

https://doi.org/10.1182/blood.V118.21.2617.2617

Published: 2011

Journal Articles

Lenalidomide (LMID) Significantly Enhances Circulating Serum Levels of IL-2 and IL-15 Levels, NK Expansion and Activation and NK and LAK Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children’s Oncology Group Phase I Consortium Report

Janet Ayello, MS, MT, Stacey L Berg, MD, Mark Krailo, PhD, Carmella van de Ven, MS, Ashish Mark Ingle, MS, Duane Lewis, Lauren Harrison, RN, Susan Blaney, MD, Peter C. Adamson, MD, Mitchell S. Cairo, MD

Blood (2008) 112 (11): 107.

https://doi.org/10.1182/blood.V112.11.107.107

Published: 2008

Journal Articles

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma

Elizabeth Fox, Bassem I. Razzouk, Brigitte C. Widemann, Shaun Xiao, Michelle O'Brien, Wendy Goodspeed, Gregory H. Reaman, Susan M. Blaney, Anthony J. Murgo, Frank M. Balis, Peter C. Adamson

Blood (2008) 111 (2): 566–573.

https://doi.org/10.1182/blood-2007-08-107839

Published: 2008

Journal Articles

Effective Targeting of Leukemic Cells in Children with B-Precursor Acute Lymphoblastic Leukemia Treated with Anti-CD22 (Epratuzumab). A Children’s Oncology Group (COG) Study.

Michael J. Borowitz, MD, PhD, William L. Carroll, MD, Peter C. Adamson, MD, Mitchell S. Cairo, MD, David M. Goldenberg, ScD, MD, William A. Wegener, MD,PhD, Elizabeth Raetz, MD

Blood (2006) 108 (11): 2585.

https://doi.org/10.1182/blood.V108.11.2585.2585

Published: 2006

Journal Articles

Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound Genasense TM (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations.

Blaine W. Robinson, PhD, Kathyrn C. Behling, MD, PhD, Jeffrey S. Barrett, PhD, Manish Gupta, PhD, Jessicca M. Rege, PhD, Jonni S. Moore, PhD, Andrew D. Bantly, Junhyong Kim, PhD, George Hii, Cheryl L. Willman, MD, Jeffrey Potter, Peter C. Adamson, MD, Carolyn A. Felix, MD

Blood (2005) 106 (11): 3360.

https://doi.org/10.1182/blood.V106.11.3360.3360

Published: 2005

Journal Articles

Pan-BCL-2 Family Small Molecule Inhibitor GX015-070 (GeminX, Inc.) Exhibits Single Agent Cytotoxicity, Is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations.

Jessicca M. Rege, PhD, Blaine W. Robinson, PhD, Manish Gupta, PhD, Jeffrey S. Barrett, PhD, Peter C. Adamson, MD, Kathryn C. Behling, MD, PhD, Andrew D. Bantly, Jonni S. Moore, PhD, Carolyn A. Felix, MD

Blood (2005) 106 (11): 3368.

https://doi.org/10.1182/blood.V106.11.3368.3368

Published: 2005

NARROW

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2

Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group

Lenalidomide (LMID) Significantly Enhances Circulating Serum Levels of IL-2 and IL-15 Levels, NK Expansion and Activation and NK and LAK Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children’s Oncology Group Phase I Consortium Report

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma

Effective Targeting of Leukemic Cells in Children with B-Precursor Acute Lymphoblastic Leukemia Treated with Anti-CD22 (Epratuzumab). A Children’s Oncology Group (COG) Study.

Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound Genasense TM (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations.

Pan-BCL-2 Family Small Molecule Inhibitor GX015-070 (GeminX, Inc.) Exhibits Single Agent Cytotoxicity, Is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only